JP2013526579A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013526579A5 JP2013526579A5 JP2013511357A JP2013511357A JP2013526579A5 JP 2013526579 A5 JP2013526579 A5 JP 2013526579A5 JP 2013511357 A JP2013511357 A JP 2013511357A JP 2013511357 A JP2013511357 A JP 2013511357A JP 2013526579 A5 JP2013526579 A5 JP 2013526579A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- phenyl
- administered
- amount
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- -1 2-fluoro-4-iodo - phenylamino Chemical group 0.000 claims 8
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 150000004682 monohydrates Chemical class 0.000 claims 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims 3
- 150000001412 amines Chemical class 0.000 claims 2
- 238000012423 maintenance Methods 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34708110P | 2010-05-21 | 2010-05-21 | |
| US61/347,081 | 2010-05-21 | ||
| US37434310P | 2010-08-17 | 2010-08-17 | |
| US61/374,343 | 2010-08-17 | ||
| PCT/US2011/037146 WO2011146712A1 (en) | 2010-05-21 | 2011-05-19 | Combination |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013526579A JP2013526579A (ja) | 2013-06-24 |
| JP2013526579A5 true JP2013526579A5 (https=) | 2014-07-03 |
| JP5858989B2 JP5858989B2 (ja) | 2016-02-10 |
Family
ID=44992060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013511357A Expired - Fee Related JP5858989B2 (ja) | 2010-05-21 | 2011-05-19 | 組合せ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9180129B2 (https=) |
| EP (1) | EP2571358B1 (https=) |
| JP (1) | JP5858989B2 (https=) |
| ES (1) | ES2530755T3 (https=) |
| WO (1) | WO2011146712A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2913048A1 (en) | 2014-02-27 | 2015-09-02 | ratiopharm GmbH | Pharmaceutical composition comprising trametinib |
| US20190365741A1 (en) * | 2015-08-28 | 2019-12-05 | Novartis Ag | Combinations of the cdk4/6 inhibitor lee011 and the mek1/2 inhibitor trametinib, optionally further comprising the pi3k inhibitor byl719 to treat cancer |
| WO2018183762A1 (en) * | 2017-03-29 | 2018-10-04 | United States Government As Represented By The Department Of Veterans Affairs | Methods and compositions for treating cancer |
| US11998550B2 (en) | 2017-04-20 | 2024-06-04 | Thomas Jefferson University | Trametinib prevents mesothelial-mesenchymal transition and ameliorates abdominal adhesion and pulmonary fibrosis formation |
| KR20220010707A (ko) * | 2019-06-18 | 2022-01-26 | 주식회사 스탠다임 | 대사성 간질환의 예방 또는 치료용 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| PL204958B1 (pl) * | 2000-06-30 | 2010-02-26 | Glaxo Group Ltd | Ditosylany związków chinazolinowych, środek farmaceutyczny i zastosowanie tych związków |
| US7378423B2 (en) * | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| AU2005252110B2 (en) | 2004-06-11 | 2008-09-04 | Shionogi & Co., Ltd. | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-D] pyrimidine derivatives and related compounds for the treatment of cancer |
| CA2606207C (en) | 2005-04-19 | 2014-11-18 | Smithkline Beecham (Cork) Limited | Pharmaceutical composition |
| EP2088862A4 (en) | 2006-11-28 | 2009-12-02 | Smithkline Beecham Cork Ltd | METHOD OF TREATING CANCER |
-
2011
- 2011-05-19 ES ES11784240T patent/ES2530755T3/es active Active
- 2011-05-19 EP EP11784240.1A patent/EP2571358B1/en not_active Not-in-force
- 2011-05-19 WO PCT/US2011/037146 patent/WO2011146712A1/en not_active Ceased
- 2011-05-19 US US13/699,077 patent/US9180129B2/en not_active Expired - Fee Related
- 2011-05-19 JP JP2013511357A patent/JP5858989B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2810852T3 (es) | Compuestos y composiciones para inhibir la actividad de shp2 | |
| JP6892381B2 (ja) | 多発性骨髄腫を治療するための薬物の組み合わせ | |
| JP2006182786A5 (https=) | ||
| JP2014505107A5 (https=) | ||
| JP2014518266A5 (https=) | ||
| JP2011507896A5 (https=) | ||
| JP2013509429A5 (https=) | ||
| JP2014503593A5 (https=) | ||
| JP2019501133A5 (https=) | ||
| JP2009513662A5 (https=) | ||
| JP2015536986A5 (https=) | ||
| JP2014505735A5 (https=) | ||
| JP2011057693A5 (https=) | ||
| JP2012255026A5 (https=) | ||
| JP2013510120A5 (https=) | ||
| JP2017504635A5 (https=) | ||
| JP2014526503A5 (https=) | ||
| JP2015523397A5 (https=) | ||
| JP2015511609A5 (https=) | ||
| JP2016525097A5 (https=) | ||
| JP2012515787A5 (https=) | ||
| JP2013526579A5 (https=) | ||
| JP6014142B2 (ja) | Ｎ−ヒドロキシ−４−｛２−［３−（ｎ，ｎ−ジメチルアミノメチル）ベンゾフラン−２−イルカルボニルアミノ］エトキシ｝ベンズアミドの投与に関するスキーム | |
| JP2012522841A5 (https=) | ||
| RU2016116789A (ru) | Комбинация энзалутамида и афурезертиба для лечения рака |